January 18, 2019 | English | عربي
Add to Twitter
 
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna
• Collaboration seeks to develop novel treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH)